De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Titled "De Novo Protein Sequencing of Antibodies for Identification of Neutralizing Antibodies in Human Plasma Post SARS-CoV-2 Vaccination," the study highlights how de novo antibody sequencing, a method that identifies antibodies directly from blood samples without relying on genetic databases, provides valuable information on unique and functional antibodies present in serum. By leveraging de novo antibody sequencing, the study identified antibodies that were not present in traditional B-cell sequencing data, underscoring the significance of this innovative and complementary approach.

The study also revealed that monoclonal antibodies (mAbs) derived from polyclonal antibodies (pAbs) retained strong affinities, similar or even better than the original pAb with potent neutralizing capabilities against SARS-CoV-2. These findings open new avenues for developing highly specific and effective therapeutics.

With 100+ polyclonal antibody sequencing projects under their belt and a 100 % success rate, the team at Rapid Novor is actively working with pharmaceutical companies and biotechnology partners to integrate REpAb^® into critical workflows for the discovery of highly potent and developable antibodies.

Source:

Rapid Novor